中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(10): 2082-2086

Therapeutic paradigms and potential therapies for nonalcoholic steatohepatitis

DOI: 10.12449/JCH241025
  • 1a.

    Office of Clinical Trial Institutions for Drug and Medical Devices，The FAW General Hospital of Jilin Province，Changchun 130000，China

  • 1b.

    Department of Drug Management，The FAW General Hospital of Jilin Province，Changchun 130000，China

  • 2.

    Department of Pharmacy，The Second Hospital of Changchun，Changchun 130000，China

Research funding:

Jilin Provincial Department of Science and Technology Project (20210401054YY)

More Information
  • Corresponding author: LI Feng， 18943994025@163.com （ORCID： 0009-0009-8760-3675）
  • Received Date: 2024-02-21
  • Accepted Date: 2024-03-26
  • Published Date: 2024-10-25
    Abstract
  • In recent years， steady progress has been made in the epidemiology， pathogenesis， and therapeutic targets of nonalcoholic steatohepatitis （NASH）， while there has been slow progress in the field of therapeutic drug development. This article reviews the advances in lifestyle intervention， surgical methods， gut microbiota， and drugs in the treatment of NASH， especially the role of insulin sensitizers， antioxidants， cholesterol-lowering drugs， thyroid hormone mimetics， incretins， and cytokines in the treatment of NASH， in order to provide more methods and options for the treatment of NASH in the future.

     

    • FullText(HTML)
  • loading
    • References(49)
  • [1]
    ZEIGERER A. NAFLD-A rising metabolic disease[J]. Mol Metab, 2021, 50: 101274. DOI: 10.1016/j.molmet.2021.101274.
    [2]
    WANG YK, WEI SY, LIU C, et al. A new definition of fatty liver disease: from nonalcoholic fatty liver disease to metabolic associated fatty liver disease[J]. Chin J Dig Surg, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080.

    王永康, 魏诗雨, 刘昌, 等. 脂肪性肝病新定义:从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病[J]. 中华消化外科杂志, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080.
    [3]
    DUELL PB, WELTY FK, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American heart association[J]. Arterioscler Thromb Vasc Biol, 2022, 42( 6): e168- e185. DOI: 10.1161/ATV.0000000000000153.
    [4]
    CIARDULLO S, BALLABENI C, TREVISAN R, et al. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: A systematic review and meta-analysis[J]. Biomolecules, 2022, 12( 1): 105. DOI: 10.3390/biom12010105.
    [5]
    BJÖRKSTRÖM K, WIDMAN L, HAGSTRÖM H. Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study[J]. Liver Int, 2022, 42( 4): 820- 828. DOI: 10.1111/liv.15195.
    [6]
    ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69( 4): 896- 904. DOI: 10.1016/j.jhep.2018.05.036.
    [7]
    POUWELS S, SAKRAN N, GRAHAM Y, et al. Non-alcoholic fatty liver disease(NAFLD): A review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22( 1): 63. DOI: 10.1186/s12902-022-00980-1.
    [8]
    HYDES TJ, RAVI S, LOOMBA R, et al. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH[J]. Clin Mol Hepatol, 2020, 26( 4): 383- 400. DOI: 10.3350/cmh.2020.0067.
    [9]
    YOUNOSSI ZM, COREY KE, LIM JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review[J]. Gastroenterology, 2021, 160( 3): 912- 918. DOI: 10.1053/j.gastro.2020.11.051.
    [10]
    HANNAH WN Jr, HARRISON SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease[J]. Clin Liver Dis, 2016, 20( 2): 339- 350. DOI: 10.1016/j.cld.2015.10.008.
    [11]
    SUN J, RUAN YT, XU NN, et al. The effect of dietary carbohydrate and calorie restriction on weight and metabolic health in overweight/obese individuals: A multi-center randomized controlled trial[J]. BMC Med, 2023, 21( 1): 192. DOI: 10.1186/s12916-023-02869-9.
    [12]
    WEI XY, LIN BQ, HUANG Y, et al. Effects of time-restricted eating on nonalcoholic fatty liver disease: The TREATY-FLD randomized clinical trial[J]. JAMA Netw Open, 2023, 6( 3): e233513. DOI: 10.1001/jamanetworkopen.2023.3513.
    [13]
    CASTAGNETO-GISSEY L, CASELLA-MARIOLO J, MINGRONE G. Bariatric/metabolic surgery[J]. Handb Exp Pharmacol, 2022, 274: 371- 386. DOI: 10.1007/164_2021_565.
    [14]
    VERRASTRO O, PANUNZI S, CASTAGNETO-GISSEY L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis(BRAVES): A multicentre, open-label, randomised trial[J]. Lancet, 2023, 401( 10390): 1786- 1797. DOI: 10.1016/S0140-6736(23)00634-7.
    [15]
    TILG H, ADOLPH TE, TRAUNER M. Gut-liver axis: Pathophysiological concepts and clinical implications[J]. Cell Metab, 2022, 34( 11): 1700- 1718. DOI: 10.1016/j.cmet.2022.09.017.
    [16]
    LIU LL, ZHANG JH, CHENG Y, et al. Gut microbiota: A new target for T2DM prevention and treatment[J]. Front Endocrinol(Lausanne), 2022, 13: 958218. DOI: 10.3389/fendo.2022.958218.
    [17]
    ALVES CC, WAITZBERG DL, de ANDRADE LS, et al. Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver[J]. Front Microbiol, 2017, 8: 2010. DOI: 10.3389/fmicb.2017.02010.
    [18]
    XUE LF, DENG ZL, LUO WH, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial[J]. Front Cell Infect Microbiol, 2022, 12: 759306. DOI: 10.3389/fcimb.2022.759306.
    [19]
    SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci, 2021, 22( 8): 4156. DOI: 10.3390/ijms22084156.
    [20]
    BELL DSH, JERKINS T. In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome[J]. Diabetes Obes Metab, 2023, 25( 11): 3093- 3102. DOI: 10.1111/dom.15222.
    [21]
    LEWIS J, HABEL L, QUESENBERRY C, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes[J]. JAMA, 2015, 314( 3): 265- 77. DOI: 10.1001/jama.2015.7996.
    [22]
    WABITSCH S, MCCALLEN JD, KAMENYEVA O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD[J]. J Hepatol, 2022, 77( 3): 748- 760. DOI: 10.1016/j.jhep.2022.03.010.
    [23]
    HARRISON SA, ALKHOURI N, DAVISON BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study[J]. J Hepatol, 2020, 72( 4): 613- 626. DOI: 10.1016/j.jhep.2019.10.023.
    [24]
    CHEN Z, TIAN RF, SHE ZG, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J]. Free Radic Biol Med, 2020, 152: 116- 141. DOI: 10.1016/j.freeradbiomed.2020.02.025.
    [25]
    NAGASHIMADA M, OTA T. Role of vitamin E in nonalcoholic fatty liver disease[J]. IUBMB Life, 2019, 71( 4): 516- 522. DOI: 10.1002/iub.1991.
    [26]
    SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362( 18): 1675- 1685. DOI: 10.1056/NEJMoa0907929.
    [27]
    LOH WQ, YOUN J, SEOW WJ. Vitamin E intake and risk of prostate cancer: A meta-analysis[J]. Nutrients, 2022, 15( 1): 14. DOI: 10.3390/nu15010014.
    [28]
    ĆULAFIĆ M, VEZMAR-KOVAČEVIĆ S, DOPSAJ V, et al. Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis[J]. J Med Biochem, 2020, 39( 3): 290- 298. DOI: 10.2478/jomb-2019-0043.
    [29]
    ZHU XX, WU M, WANG H, et al. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: A double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study[J]. Expert Opin Investig Drugs, 2021, 30( 5): 579- 589. DOI: 10.1080/13543784.2021.1900822.
    [30]
    HU Y, LI HJ, ZHANG H, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial[J]. Nat Commun, 2023, 14( 1): 6409. DOI: 10.1038/s41467-023-42162-0.
    [31]
    SAFADI R, KONIKOFF FM, MAHAMID M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2014, 12( 12): 2085- 2091. e 1. DOI: 10.1016/j.cgh.2014.04.038.
    [32]
    MALIK A, NADEEM M, AMJAD W, et al. Effects of Aramchol in patients with nonalcoholic fatty liver disease(NAFLD). A systematic review and meta-analysis[J]. Prz Gastroenterol, 2023, 18( 1): 67- 75. DOI: 10.5114/pg.2022.113573.
    [33]
    WANG CE, XU WT, GONG J, et al. Research progress on the treatment of non-alcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [34]
    KANNT A, WOHLFART P, MADSEN AN, et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis[J]. Br J Pharmacol, 2021, 178( 12): 2412- 2423. DOI: 10.1111/bph.15427.
    [35]
    MAVROMATI M, JORNAYVAZ FR. Hypothyroidism-associated dyslipidemia: Potential molecular mechanisms leading to NAFLD[J]. Int J Mol Sci, 2021, 22( 23): 12797. DOI: 10.3390/ijms222312797.
    [36]
    HU LY, GU YP, LIANG J, et al. Discovery of highly potent and selective thyroid hormone receptor β agonists for the treatment of nonalcoholic steatohepatitis[J]. J Med Chem, 2023, 66( 5): 3284- 3300. DOI: 10.1021/acs.jmedchem.2c01669.
    [37]
    KARIM G, BANSAL MB. Resmetirom: An orally administered, smallmolecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. touchREV Endocrinol, 2023, 19( 1): 60- 70. DOI: 10.17925/EE.2023.19.1.60.
    [38]
    HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390( 6): 497- 509. DOI: 10.1056/NEJMoa2309000.
    [39]
    LOOMBA R, NEUTEL J, BERNARD D, et al. VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat in patients with non-alcoholic fatty liver disease: a phase 2 randomized, placebo-controlled trial[J]. Hepatology, 2018,( 6): 68. DOI: 10.1016/s0168-8278(20)30652-8.
    [40]
    LI QX, GAO H, GUO YX, et al. GLP-1 and underlying beneficial actions in Alzheimer’s disease, hypertension, and NASH[J]. Front Endocrinol, 2021, 12: 721198. DOI: 10.3389/fendo.2021.721198.
    [41]
    BERNSMEIER C, MEYER-GERSPACH AC, BLASER LS, et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease[J]. PLoS One, 2014, 9( 1): e87488. DOI: 10.1371/journal.pone.0087488.
    [42]
    NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384( 12): 1113- 1124. DOI: 10.1056/NEJMoa2028395.
    [43]
    JASTREBOFF AM, KAPLAN LM, FRÍAS JP, et al. Triple-hormone-receptor agonist retatrutide for obesity- A phase 2 trial[J]. N Engl J Med, 2023, 389( 6): 514- 526. DOI: 10.1056/NEJMoa2301972.
    [44]
    DUAN YM, PAN XF, LUO JY, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 880298. DOI: 10.3389/fimmu.2022.880298.
    [45]
    FONTES-CAL TCM, MATTOS RT, MEDEIROS NI, et al. Crosstalk between plasma cytokines, inflammation, and liver damage as a new strategy to monitoring NAFLD progression[J]. Front Immunol, 2021, 12: 708959. DOI: 10.3389/fimmu.2021.708959.
    [46]
    ALAAEDDINE N, SIDAOUI J, HILAL G, et al. TNF-α messenger ribonucleic acid(mRNA) in patients with nonalcoholic steatohepatitis[J]. Eur Cytokine Netw, 2012, 23( 3): 107- 111. DOI: 10.1684/ecn.2012.0313.
    [47]
    AHMED H, UMAR MI, IMRAN S, et al. TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop[J]. Exp Mol Pathol, 2022, 124: 104733. DOI: 10.1016/j.yexmp.2021.104733.
    [48]
    WIDJAJA AA, SINGH BK, ADAMI E, et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis[J]. Gastroenterology, 2019, 157( 3): 777- 792. e 14. DOI: 10.1053/j.gastro.2019.05.002.
    [49]
    ANSTEE QM, NEUSCHWANDER-TETRI BA, WAI-SUN WONG V, et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase Ⅲ randomized study[J]. Clin Gastroenterol Hepatol, 2024, 22( 1): 124- 134. e 1. DOI: 10.1016/j.cgh.2023.04.003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (166) PDF downloads(43) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return